← Leaderboards
Linda S Cook
University Of Colorado Denver
$4,558,506
Attributed
$6,130,381
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,130,381 · 4
By mechanism
R01$3,622,026 · 2
UG1$2,357,813 · 1
R03$150,542 · 1
Top collaborators
- Stacey Honda3 shared
- Debra P Ritzwoller3 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Julie A Marshall$13,132,805
- Stacey Honda$785,938
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesOvarianMalignant Neoplasm Of OvaryFollow-UpSiteWomanTumorMalignant Female Reproductive System NeoplasmHistologyCancer PatientDiagnosisCancer TherapyCohortRecurrent DiseaseBritish ColumbiaAlberta ProvincePathologyMalignant NeoplasmsAccountingMedicalMedical RecordsPopulation BasedMalignant Neoplasm Of LungMortality
Grant awards (15)
Improving Strategies for Cancer Reduction through Early-detection and ENgagement (I-SCREEN)$893,587
UG1 · FY2025 · CA · contact PI
NOT-CA-24-111 Improving Strategies for Cancer Reduction through Early-detection and ENgagement (I-SCREEN)$534,586
UG1 · FY2025 · CA · contact PI
Improving Strategies for Cancer Reduction through Early-detection and ENgagement (I-SCREEN)$929,640
UG1 · FY2024 · CA · contact PI
A Population Based Study of Ketorolac and Ovarian Cancer Survival$302,341
R01 · FY2023 · CA · contact PI
A Population Based Study of Ketorolac and Ovarian Cancer Survival$338,423
R01 · FY2022 · CA · contact PI
A Population Based Study of Ketorolac and Ovarian Cancer Survival$193,723
R01 · FY2021 · CA · contact PI
A Population Based Study of Ketorolac and Ovarian Cancer Survival$184,469
R01 · FY2021 · CA · contact PI
A Population Based Study of Ketorolac and Ovarian Cancer Survival$392,750
R01 · FY2020 · CA · contact PI
Mitochondrial DNA and Ovarian Cancer Risk and Survival$318,673
R01 · FY2016 · CA · contact PI
Mitochondrial DNA and Ovarian Cancer Risk and Survival$505,309
R01 · FY2015 · CA · contact PI
Mitochondrial DNA and Ovarian Cancer Risk and Survival$397,213
R01 · FY2014 · CA · contact PI
Mitochondrial DNA and Ovarian Cancer Risk and Survival$446,270
R01 · FY2013 · CA · contact PI
Mitochondrial DNA and Ovarian Cancer Risk and Survival$542,855
R01 · FY2012 · CA · contact PI
Uterine cancer survival disparities, Hispanic ethnicity, and comorbidities.$75,292
R03 · FY2010 · CA · contact PI
Uterine cancer survival disparities, Hispanic ethnicity, and comorbidities.$75,250
R03 · FY2009 · CA · contact PI